Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada
Introduction Opioid use disorder (OUD) during pregnancy is associated with increased rates of adverse perinatal, foetal and neonatal health events. Opioid agonist treatment (OAT) can substantially reduce the risk of these potential harms. In British Columbia (BC), methadone and buprenorphine/naloxon...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-08-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/8/e095461.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849393952045662208 |
|---|---|
| author | Lianping Ti Bohdan Nosyk Jeong Eun Min B Carolina Guerra-Alejos Megan Kurz Lindsay A Wilson |
| author_facet | Lianping Ti Bohdan Nosyk Jeong Eun Min B Carolina Guerra-Alejos Megan Kurz Lindsay A Wilson |
| author_sort | Lianping Ti |
| collection | DOAJ |
| description | Introduction Opioid use disorder (OUD) during pregnancy is associated with increased rates of adverse perinatal, foetal and neonatal health events. Opioid agonist treatment (OAT) can substantially reduce the risk of these potential harms. In British Columbia (BC), methadone and buprenorphine/naloxone are first-line treatment options for pregnant people with OUD. However, the comparative effectiveness of these regimens during pregnancy remains poorly understood, particularly in terms of how dosage may impact clinical outcomes. This protocol outlines a proposed population-based retrospective study to evaluate the comparative effectiveness of methadone compared with buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes.Methods and analysis We propose to conduct a retrospective observational study using population-based data from individuals who received methadone or buprenorphine/naloxone during pregnancy between 1 April 2010 and 31 March 2022. Data will be collected from 10 linked population-level administrative databases. We will emulate target trials using intention-to-treat and per-protocol approaches. We will use a pooled logistic regression approach to assess the impact of methadone versus buprenorphine/naloxone on time to OAT episode discontinuation and a dose-response marginal structural model to evaluate neonatal health at delivery. An exploratory observational analysis will also be conducted to describe the impact of methadone vs buprenorphine exposure during the first trimester of pregnancy on congenital malformations and anomalies.Ethics and dissemination This study has been determined to meet the criteria for exemption per Article 2.5 of the 2018 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Study databases have been made available by the BC Ministries of Health and Mental Health and Addiction as part of the provincial opioid overdose public health emergency response. Results will be disseminated to policymakers, clinical partners, community programmes and people with lived and living experience of substance use and published in peer-reviewed journals. |
| format | Article |
| id | doaj-art-6cf2a27ea7da4c2280b2c7f0620f9312 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-6cf2a27ea7da4c2280b2c7f0620f93122025-08-20T03:40:14ZengBMJ Publishing GroupBMJ Open2044-60552025-08-0115810.1136/bmjopen-2024-095461Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, CanadaLianping Ti0Bohdan Nosyk1Jeong Eun Min2B Carolina Guerra-Alejos3Megan Kurz4Lindsay A Wilson5British Columbia Centre on Substance Use, Vancouver, British Columbia, CanadaCentre for Advancing Health Outcomes, Vancouver, British Columbia, CanadaCentre for Advancing Health Outcomes, Vancouver, British Columbia, CanadaCentre for Advancing Health Outcomes, Vancouver, British Columbia, CanadaCentre for Advancing Health Outcomes, Vancouver, British Columbia, CanadaSchool of Population and Public Health, University of British Columbia, Vancouver, British Columbia, CanadaIntroduction Opioid use disorder (OUD) during pregnancy is associated with increased rates of adverse perinatal, foetal and neonatal health events. Opioid agonist treatment (OAT) can substantially reduce the risk of these potential harms. In British Columbia (BC), methadone and buprenorphine/naloxone are first-line treatment options for pregnant people with OUD. However, the comparative effectiveness of these regimens during pregnancy remains poorly understood, particularly in terms of how dosage may impact clinical outcomes. This protocol outlines a proposed population-based retrospective study to evaluate the comparative effectiveness of methadone compared with buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes.Methods and analysis We propose to conduct a retrospective observational study using population-based data from individuals who received methadone or buprenorphine/naloxone during pregnancy between 1 April 2010 and 31 March 2022. Data will be collected from 10 linked population-level administrative databases. We will emulate target trials using intention-to-treat and per-protocol approaches. We will use a pooled logistic regression approach to assess the impact of methadone versus buprenorphine/naloxone on time to OAT episode discontinuation and a dose-response marginal structural model to evaluate neonatal health at delivery. An exploratory observational analysis will also be conducted to describe the impact of methadone vs buprenorphine exposure during the first trimester of pregnancy on congenital malformations and anomalies.Ethics and dissemination This study has been determined to meet the criteria for exemption per Article 2.5 of the 2018 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Study databases have been made available by the BC Ministries of Health and Mental Health and Addiction as part of the provincial opioid overdose public health emergency response. Results will be disseminated to policymakers, clinical partners, community programmes and people with lived and living experience of substance use and published in peer-reviewed journals.https://bmjopen.bmj.com/content/15/8/e095461.full |
| spellingShingle | Lianping Ti Bohdan Nosyk Jeong Eun Min B Carolina Guerra-Alejos Megan Kurz Lindsay A Wilson Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada BMJ Open |
| title | Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada |
| title_full | Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada |
| title_fullStr | Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada |
| title_full_unstemmed | Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada |
| title_short | Comparative effectiveness of methadone versus buprenorphine/naloxone during pregnancy on perinatal and neonatal health outcomes: protocol for a population-based target trial in British Columbia, Canada |
| title_sort | comparative effectiveness of methadone versus buprenorphine naloxone during pregnancy on perinatal and neonatal health outcomes protocol for a population based target trial in british columbia canada |
| url | https://bmjopen.bmj.com/content/15/8/e095461.full |
| work_keys_str_mv | AT lianpingti comparativeeffectivenessofmethadoneversusbuprenorphinenaloxoneduringpregnancyonperinatalandneonatalhealthoutcomesprotocolforapopulationbasedtargettrialinbritishcolumbiacanada AT bohdannosyk comparativeeffectivenessofmethadoneversusbuprenorphinenaloxoneduringpregnancyonperinatalandneonatalhealthoutcomesprotocolforapopulationbasedtargettrialinbritishcolumbiacanada AT jeongeunmin comparativeeffectivenessofmethadoneversusbuprenorphinenaloxoneduringpregnancyonperinatalandneonatalhealthoutcomesprotocolforapopulationbasedtargettrialinbritishcolumbiacanada AT bcarolinaguerraalejos comparativeeffectivenessofmethadoneversusbuprenorphinenaloxoneduringpregnancyonperinatalandneonatalhealthoutcomesprotocolforapopulationbasedtargettrialinbritishcolumbiacanada AT megankurz comparativeeffectivenessofmethadoneversusbuprenorphinenaloxoneduringpregnancyonperinatalandneonatalhealthoutcomesprotocolforapopulationbasedtargettrialinbritishcolumbiacanada AT lindsayawilson comparativeeffectivenessofmethadoneversusbuprenorphinenaloxoneduringpregnancyonperinatalandneonatalhealthoutcomesprotocolforapopulationbasedtargettrialinbritishcolumbiacanada |